Investor Conference Call FY/Q Results

Size: px
Start display at page:

Download "Investor Conference Call FY/Q Results"

Transcription

1 Science For A Better Life Investor Conference Call FY/Q4 Results Werner Wenning, CEO February FY/Q4 Investor Conference Call Werner Wenning Disclaimer This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer s public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. FY/Q4 Investor Conference Call Werner Wenning Page 2 1

2 Fiscal : Successful in a difficult environment Record sales and earnings at HealthCare, record sales at, unprecedented drop in demand at Third highest group underlying EBITDA ever Restructuring, efficiency and performance projects delivered Record net cash flow Q4 underlying EBITDA back to pre-crises levels Optimistic 2010 outlook, new mid-term targets FY/Q4 Investor Conference Call Werner Wenning Page 3 Q4 Upward Trend Confirmed Key Figures EBITDA by Subgroup In million, Δ% y-o-y 7,872 EBITDA* 1,513 Δ% -1% +11% ² +16% Δ% Adj. ** +3% EBIT* 817 Core EPS % <1% Reconciliation 11% 13% 76% HealthCare * Before special items ** Currency & portfolio adjusted FY/Q4 Investor Conference Call Werner Wenning Page 4 2

3 HealthCare Strong Finish to a Successful Year Q4 Earnings In million, Δ% y-o-y Consumer Health 0% (+5%) Pharma +1% (+7%) EBITDA 1,095 1,154 +5% EBIT 1,466 2, % % % % % HealthCare 4,164m; +1% (+6%) Q4 08 Q4 Q4 08 Q4 ( ) Currency & portfolio adjusted FY/Q4 Investor Conference Call Werner Wenning Page 5 Strong Growth, Earnings Down on Fx And Weaker Prices Q4 Earnings In million, Δ% y-o-y Environmental Science/ BioScience -3% (0%) 221 Crop Protection +5% (+7%) EBITDA % EBIT % 1, % % -29% 1 0 1,398m; +3% (+6%) Q4 08 Q4 Q4 08 Q4 ( ) Currency & portfolio adjusted FY/Q4 Investor Conference Call Werner Wenning Page 6 3

4 Ongoing Recovery Earnings In million, Δ% y-o-y 2,055 1,830 1,636 2,038-2% (+1%) (y-o-y) 2, EBITDA % (y-o-y) EBIT (y-o-y) Q4 08 Q1 Q2 Q3 Q4 Q4 08 Q1 Q2 Q3 Q4 Q4 08 Q1 Q2 Q3 Q4 ( ) Currency & portfolio adjusted FY/Q4 Investor Conference Call Werner Wenning Page 7 Cash Flow and Net Debt Development Q4'09 Net Debt Development In million GCF NCF Investments ofcf In billion ,029 1, ,271 Δ % y-o-y -11% +85% -22% +291% Q3 Q4 FY GCF NCF Investments ofcf 9.7 4,658 5,375 1,575 3,800 Δ % y-o-y -12% +49% -10% +106% Q4 08 Q4 FY/Q4 Investor Conference Call Werner Wenning Page 8 4

5 Performance vs. Targets in million Outlook adj. Δ Comments HealthCare Margin* above market growth improve towards 28% 15, % 4% +90bps Pharma slightly behind, consumer in-market performance ahead Strong in pharmerging markets esp. China Margin* increase maintain 25%, Q3 update 23-24% 6, % 2.5% -190bps Gained market share Achieved targeted 2bn sales with new products Met Q4 guidance of higher sales (+6%) uebitda** ofcf*** severe decline severe decline positive 7, % -59% +214% Unprecedented drop in demand Sequential recovery clearly visible Q4 sales in Asia/Pacific above pre-crises levels FY/Q4 Investor Conference Call Werner Wenning Page 9 *underlying EBITDA margin **uebitda = pre-exceptional items ***ofcf = operating free cash flow Group: Performance vs. Targets Outlook actual Δ Comments 31-32bn 31.2bn -5.7% Record sales at HealthCare and Unprecedented drop in demand at uebitda approx. -5% 6.5bn -6.6% Includes 140m ( 80m in Q4 alone) negative currency effect At constant exchange rates decline -4.6% Net debt reduce towards 10bn 9.7bn -4.5bn Includes conversion of mandatory convertible bond Record net and ofcf Achieved 1bn trade working capital improvement (constant vol/prices) Dividend payout ratio 30-40% of Core EPS /-0 Payout ratio 38.5% Underscores optimism for future developments FY/Q4 Investor Conference Call Werner Wenning Page 10 5

6 Consistent Strong Performance EBIT in million 4,287 4,342 4,400 3,300 3,479 3,772 3,660 Group + 356% 2,920 n.m. 2,244 2, %* 1, ,440 HealthCare + 373% * % vs As reported in respective year 2002 as reported in as reported in excluding H.C. Starck and Wolff Walsrode FY/Q4 Investor Conference Call Werner Wenning Page Consistent Strong Performance 4,287 4, , , ,660 3, , , , , , , EBITDA margin in % HealthCare Group + 424% Group * % vs As reported in respective year 2002 as reported in as reported in excluding H.C. Starck and Wolff Walsrode FY/Q4 Investor Conference Call Werner Wenning Page 12 6

7 Group Outlook Fx and portfolio adjusted Δ 2010E 2012E 31.2bn -6% >5% ~5% p.a. uebitda 6.5bn -7% improve towards 7bn ~8bn Core EPS % ~10% average ~10% p.a. to ~ 5 FY/Q4 Investor Conference Call Werner Wenning Page 13 Outlook depends on planning assumptions as detailed in the annual report Subgroup Outlook 2010 And Beyond 2010E 2012E Group HealthCare at least market growth corresponds to adj. sales increase of ~5% increase in uebitda at least market growth steady improvement of uebitda slightly above market growth equivalent to adj. sales increase of ~4% small increase in uebitda business environment currently more difficult than expected at least market growth further improvement of uebitda continuing economic recovery aim to increase sales 10+% substantial increase uebitda somewhat higher sales in Q1 vs. Q4 09 and Q1 uebitda roughly level with Q4 09 FY/Q4 Investor Conference Call Werner Wenning Page 14 provided economic recovery continues, expect pre-crises sales levels of > 10bn by 2012 considerable increase of uebitda Outlook depends on planning assumptions as detailed in the annual report 7

8 Significant Newsflow From Pharma Pipeline Expected in 2010 selection Further data from EINSTEIN program in DVT treatment Xarelto Nexavar Regorafenib VEGF-Trap-Eye Riociguat Visanne Potential newsflow from products in registration Completion of ROCKET AF trial in stroke prevention in A fib patients Completion of MAGELLAN trial in VTE prevention in medically ill patients First filings in DVT treatment and in stroke prevention Phase III initiation in breast cancer Completion of NExUS lung cancer trial Initiation of phase III (colorectal cancer 3/4th line) First data from phase III program in wet-amd (VIEW program) Phase III decision for PH-ILD Launch for treatment of endometriosis (EU) Xarelto (VTE prevention after hip/knee replacement surgery) (US) Qlaira (OC and treatment of heavy/prolonged menstrual bleeding) (US) Levitra orodispersible tablet (US, EU) YAZ plus (US) FY/Q4 Investor Conference Call Werner Wenning Page 15 Fiscal : Successful in a difficult environment Record sales and earnings at HealthCare, record sales at, unprecedented drop in demand at Third highest group underlying EBITDA ever Record net cash flow Optimistic 2010 outlook, new mid-term targets FY/Q4 Investor Conference Call Werner Wenning Page 16 8

9 Science For A Better Life FY/Q4 Investor Conference Call Werner Wenning 9

Investor Conference Call Q Results

Investor Conference Call Q Results Science For A Better Life Investor Conference Call Q1 2009 Results Werner Wenning, CEO April 29 2009 Q1 2009 Investor Conference Call Werner Wenning Disclaimer This presentation may contain forward-looking

More information

Investor Conference Call

Investor Conference Call Investor Conference Call FY/Q4 2014 Results February 26, 2015 / Marijn Dekkers, CEO Disclaimer This presentation may contain forward-looking statements based on current assumptions and forecasts made by

More information

Investor Conference Call FY/Q Results

Investor Conference Call FY/Q Results For A Better Life Investor Conference Call FY/Q4 2006 Results Werner Wenning, CEO March 15 2007 Disclaimer This presentation contains forward-looking statements based on current assumptions and forecasts

More information

Investor Conference Call

Investor Conference Call Investor Conference Call Q3 2014 Results October 30, 2014 / Marijn Dekkers, CEO Page 1 Q3 2014 Investor Conference Call Marijn Dekkers Disclaimer This presentation may contain forward-looking statements

More information

Non-Deal Debt Roadshow

Non-Deal Debt Roadshow Science For A Better Life Non-Deal Debt Roadshow Johannes M. Dietsch, Finance Director December 2007 Bayer Non-Deal Debt Roadshow December 2007 Disclaimer This presentation contains forward-looking statements

More information

Q Analyst and Investor Briefing February 26, 2010

Q Analyst and Investor Briefing February 26, 2010 Q4 2009 Analyst and Investor Briefing February 26, 2010 Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Sales declined by 0.6% to 7,872m (Q4 08: 7,923m); volume 8.2%, price

More information

Science For A Better Life. Investor Handout Q V Oct 08

Science For A Better Life. Investor Handout Q V Oct 08 Science For A Better Life Investor Handout Q3 2008 V Oct 08 Important Information This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group

More information

Investor Conference Call

Investor Conference Call Investor Conference Call FY/Q4 2015 Results February 25, 2016 / Marijn Dekkers, CEO Page 1 Q4/FY 2015 Investor Conference Call Marijn Dekkers Disclaimer This presentation may contain forward-looking statements

More information

Investor Handout Q April 2012 I Leverkusen

Investor Handout Q April 2012 I Leverkusen Investor Handout Q1 2012 April 2012 I Leverkusen Science For A Better Life This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup

More information

Investor Handout. Roadshow California

Investor Handout. Roadshow California Investor Handout Roadshow California July 2012 Science For A Better Life This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup

More information

Bayer increases sales and earnings in the second quarter

Bayer increases sales and earnings in the second quarter News Release Bayer AG Communications 51368 Leverkusen Germany Tel. +49 214 30-1 www.press.bayer.com MaterialScience leaves the crisis behind Bayer increases sales and earnings in the second quarter Sales

More information

Building Growth Momentum in HealthCare

Building Growth Momentum in HealthCare Building Growth Momentum in HealthCare Marijn Dekkers, CEO September 20, 2011 UBS Life Science Conference Disclaimer This presentation may contain forward-looking statements based on current assumptions

More information

Q Analyst and Investor Briefing October 28, 2010

Q Analyst and Investor Briefing October 28, 2010 Q3 21 Analyst and Investor Briefing October 28, 21 Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Further growth in Group sales and underlying EBITDA mainly driven by business

More information

of 5 01/08/ :58

of 5 01/08/ :58 July 31, 2012 Strong business performance in the second quarter of 2012: Sales increased by 10.0 percent to a record EUR 10,177 million / CropScience and HealthCare sustained strong momentum, MaterialScience

More information

Science For A Better Life. UniCredit German Investment Conference. Dr. Alexander Rosar Head of Investor Relations September

Science For A Better Life. UniCredit German Investment Conference. Dr. Alexander Rosar Head of Investor Relations September Science For A Better Life UniCredit German Investment Conference Dr. Alexander Rosar Head of Investor Relations September 24 2008 V Sept08 Me Important Information This presentation may contain forward-looking

More information

Q Analyst and Investor Briefing October 27, 2009

Q Analyst and Investor Briefing October 27, 2009 Q3 2009 Analyst and Investor Briefing October 27, 2009 Sales declined by 7.0% to 7,392m (Q3 08: 7,948m); volume -2.8%, price -4.4%, currency +0.6%, portfolio -0.4%. Portfolio and Fx adj. sales dropped

More information

Investor Presentation

Investor Presentation Das Bild kann zurzeit nicht angezeigt werden. Das Bild kann zurzeit nicht angezeigt werden. Das Bild kann zurzeit nicht angezeigt werden. Roadshow Frankfurt Investor Presentation Dr. Marijn Dekkers CEO

More information

Investor Handout. Roadshow Scandinavia

Investor Handout. Roadshow Scandinavia Investor Handout Roadshow Scandinavia June 15/16, 2011 Science For A Better Life This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group

More information

Disclaimer. Building growth momentum. Roadshow The Netherlands / Brussels

Disclaimer. Building growth momentum. Roadshow The Netherlands / Brussels Building growth momentum Roadshow The Netherlands / Brussels October 4-5, 2011 Disclaimer This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer

More information

Q Analyst and Investor Briefing July 31, 2012

Q Analyst and Investor Briefing July 31, 2012 Q2 212 Analyst and Investor Briefing July 31, 212 Bayer raises guidance for the full year Strong business performance in the second quarter of 212 Record sales 1.2 billion (+5.% Fx and portfolio adjusted)

More information

UBS Global Life Sciences Conference Dr. Marijn Dekkers, CEO Bayer AG

UBS Global Life Sciences Conference Dr. Marijn Dekkers, CEO Bayer AG UBS Global Life Sciences Conference Dr. Marijn Dekkers, CEO Bayer AG September 20, 2012 Science For A Better Life This presentation may contain forward-looking statements based on current assumptions and

More information

Investor Handout Roadshow London Marijn Dekkers, CEO

Investor Handout Roadshow London Marijn Dekkers, CEO Investor Handout Roadshow London Marijn Dekkers, CEO May 25-26, 2011 Science For A Better Life This presentation may contain forward-looking statements based on current assumptions and forecasts made by

More information

UniCredit German Investment Conference. Building growth momentum. Dr. Alexander Rosar Head of Investor Relations. 2011, September 29, Munich

UniCredit German Investment Conference. Building growth momentum. Dr. Alexander Rosar Head of Investor Relations. 2011, September 29, Munich UniCredit German Investment Conference Building growth momentum Dr. Alexander Rosar Head of Investor Relations 2011, September 29, Munich Disclaimer This presentation may contain forward-looking statements

More information

Q Analyst and Investor Briefing April 29, 2009

Q Analyst and Investor Briefing April 29, 2009 Q1 2009 Analyst and Investor Briefing April 29, 2009 Sales declined by 7.5% to 7,895m (Q1 08: 8,536m); Volume -9.4%, price -0.3%, currency +1.9%, portfolio +0.3%. Portfolio and Fx adj. sales dropped by

More information

News Release. Bayer: operating performance on track. Financial News Conference on fiscal 2010:

News Release. Bayer: operating performance on track. Financial News Conference on fiscal 2010: News Release Bayer AG Communications 51368 Leverkusen Germany Tel. +49 214 30-1 www.press.bayer.com Financial News Conference on fiscal 2010: Bayer: operating performance on track Group targets achieved

More information

Building a world class innovation company

Building a world class innovation company Das Bild kann zurzeit nicht angezeigt werden. Das Bild kann zurzeit nicht angezeigt werden. Das Bild kann zurzeit nicht angezeigt werden. Cheuvreux German Corporate Conference Building a world class innovation

More information

Building Growth Momentum in HealthCare. 30 th Annual J.P. Morgan Healthcare Conference

Building Growth Momentum in HealthCare. 30 th Annual J.P. Morgan Healthcare Conference 30 th Annual J.P. Morgan Healthcare Conference Building Growth Momentum in HealthCare Dr. Jörg Reinhardt Chairman of the Board of Management Bayer HealthCare 2012, January 10, San Francisco Disclaimer

More information

Bayer boosts third-quarter earnings: operating result doubled

Bayer boosts third-quarter earnings: operating result doubled Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Fall Financial News Conference of Bayer AG Bayer boosts third-quarter earnings: operating result doubled Third-quarter

More information

Lehman Conference, April 2003

Lehman Conference, April 2003 Lehman Conference, April 2003 Klaus Kühn, CFO of Bayer AG Safe Harbor This presentation contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various

More information

September 18, 2014 / Marijn Dekkers, CEO

September 18, 2014 / Marijn Dekkers, CEO Transforming Bayer into a Pure Life Company - Exit of Material September 18, 2014 / Marijn Dekkers, CEO Page 1 Investor Conference Call Marijn Dekkers September 18, 2014 Disclaimer This presentation may

More information

Q Analyst and Investor Briefing July 28, 2011

Q Analyst and Investor Briefing July 28, 2011 Q2 211 Analyst and Investor Briefing July 28, 211 Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Group sales at 9,252 million, up 5.4% (portfolio and currency adjusted) Price

More information

Q Analyst and Investor Briefing March 3, 2009

Q Analyst and Investor Briefing March 3, 2009 Q4 2008 Analyst and Investor Briefing March 3, 2009 Sales declined by 1.5% to 7,923m (Q4 07: 8,040m); Volume -5.7%, price +1.7%, currency +2.0%, portfolio +0.6%. Portfolio and Fx adj. sales dropped by

More information

News Release. Bayer: sales and EBIT at record levels. Financial and innovation targets for 2011 achieved

News Release. Bayer: sales and EBIT at record levels. Financial and innovation targets for 2011 achieved News Release Bayer AG Communications 51368 Leverkusen Germany Tel. +49 214 30-1 www.press.bayer.com Financial and innovation targets for 2011 achieved Bayer: sales and EBIT at record levels Sales increase

More information

Investor News. Another record year for Bayer. Fiscal 2015:

Investor News. Another record year for Bayer. Fiscal 2015: Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Fiscal 2015: Another record year for Bayer Focus on the Life Sciences following the successful stock market flotation

More information

Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG:

Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG: Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG: Bayer has outstanding perspectives as a pure

More information

Investor News. Bayer: strong business momentum continues and portfolio transformation underway. Fiscal 2014:

Investor News. Bayer: strong business momentum continues and portfolio transformation underway. Fiscal 2014: Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Fiscal 2014: Bayer: strong business momentum continues and portfolio transformation underway Group portfolio to

More information

Management Board Chairman Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG:

Management Board Chairman Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG: Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Management Board Chairman Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG: Bayer has great potential

More information

Investor Conference Call

Investor Conference Call Investor Conference Call /////////// Q2 2018 Results September 05, 2018 Werner Baumann, CEO Wolfgang Nickl, CFO Cautionary Statements Regarding Forward-Looking Information Certain statements contained

More information

Merck FY/Q Financial Summary for Investors and Analysts

Merck FY/Q Financial Summary for Investors and Analysts Merck FY/Q4 2017 Financial Summary for Investors and Analysts Performance amid headwinds: Healthcare sound core business; successful launches of Mavenclad & Bavencio Life Science strong performance above

More information

Third Quarter Results 2005

Third Quarter Results 2005 Science For A Better Life Company Presentation Third Quarter Results 25 Forward Looking Statements This presentation contains forward-looking statements based on current assumptions and forecasts made

More information

Investor Conference Call

Investor Conference Call Investor Conference Call Q3 2017 Results October 26, 2017 / Werner Baumann, CEO Cautionary Statements Regarding Forward- Looking Information Certain statements contained in this communication may constitute

More information

Annual Stockholders Meeting Cologne, April 27, Address by. Werner Wenning, Chairman of the Board of Management. (Please check against delivery)

Annual Stockholders Meeting Cologne, April 27, Address by. Werner Wenning, Chairman of the Board of Management. (Please check against delivery) News Release Bayer AG Communications D-51368 Leverkusen Germany Tel.: +49 214 30-1 www.news.bayer.com Annual Stockholders Meeting Cologne, April 27, 2007 Address by Werner Wenning, Chairman of the Board

More information

Acquisition of Merck s Consumer Care Business & Pharma sgc Cooperation

Acquisition of Merck s Consumer Care Business & Pharma sgc Cooperation Acquisition of Merck s Consumer Care Business & Pharma sgc Cooperation Investor Conference Call May 6, 2014 / Marijn Dekkers, CEO Page 1 Investor Conference Call Marijn Dekkers May 6, 2014 Disclaimer This

More information

CropScience Analyst & Investor Days

CropScience Analyst & Investor Days CropScience Analyst & Investor Days September 5 & 6, 2005 Lyon, France CropScience Analyst & Investor Days Efficiency Improvement and Business Excellence September 5-6, 2005 Lyon, France Dr. Dirk Suwelack

More information

Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG:

Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG: Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG: Innovation is our future 2015 was a very successful

More information

Merck FY/Q Financial Summary for Investors and Analysts

Merck FY/Q Financial Summary for Investors and Analysts Merck FY/Q4 2016 Financial Summary for Investors and Analysts A successful year: Healthcare solid commercial performance and first pipeline filings Life Science above-market growth amid seamless integration

More information

Spring Investor Conference 2003

Spring Investor Conference 2003 Spring Investor Conference 2003 Rolf Classon, Bayer HealthCare Safe Harbor This presentation contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management.

More information

Interim Report. Third Quarter of Bayer posts strong earnings growth

Interim Report. Third Quarter of Bayer posts strong earnings growth Interim Report Third of Bayer posts strong earnings growth 2 Bayer Interim Report Key Data Bayer Group Key Data Change Change Full Year million million % million million % million Sales 9,967 11,036 +

More information

Q Analyst and Investor Briefing February 28, 2018

Q Analyst and Investor Briefing February 28, 2018 Q4 217 Analyst and Investor Briefing February 28, 218 Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Q4 217: Sales at 8,596 million (+2.7% Fx & portf. adj.) EBITDA before special

More information

Investor Handout Q Results

Investor Handout Q Results Investor Handout Q3 Results Safe Harbor This presentation contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks,

More information

Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG:

Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer AG: News Release Bayer AG Communications, Government Relations & Corporate Brand 51368 Leverkusen Germany Tel. +49 214 30-1 www.news.bayer.com Dr. Marijn Dekkers at the Annual Stockholders Meeting of Bayer

More information

Q Analyst and Investor Briefing September 5, 2018

Q Analyst and Investor Briefing September 5, 2018 Q2 218 Analyst and Investor Briefing September 5, 218 Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer completes biggest acquisition in its history Monsanto business included

More information

Analyst & Investor Fact Sheet Q3 2018

Analyst & Investor Fact Sheet Q3 2018 Evonik Group in million Q3 2017 yoy Δ% Q2 2018 qoq Δ% External sales 3,556 3,794 7% 3,870 3,794-2% 3,756 Volume (%) -1% 3% Price (%) 9% 4% Exchange Rates (%) -1% -2% Other effects (%) 0% 1% Adjusted EBITDA

More information

Merck FY/Q Financial Summary for Investors and Analysts

Merck FY/Q Financial Summary for Investors and Analysts Merck FY/Q4 2018 Financial Summary for Investors and Analysts A year of investments and delivery on Guidance Healthcare Solid organic growth of 5.2% driven by resilient core business with 3% organic growth

More information

FY 2014 Results Presentation. Uwe Röhrhoff, CEO Rainer Beaujean, CFO Duesseldorf, February 11, 2015

FY 2014 Results Presentation. Uwe Röhrhoff, CEO Rainer Beaujean, CFO Duesseldorf, February 11, 2015 FY 2014 Results Presentation Uwe Röhrhoff, CEO Rainer Beaujean, CFO Duesseldorf, February 11, 2015 Disclaimer 1. This presentation may contain certain forward-looking statements, including assumptions,

More information

Stockholders Newsletter

Stockholders Newsletter Stockholders Newsletter Half-Year Financial Report as of June 30, Bayer continues on a path of growth 8 For direct access to a chapter, simply click on its name. Interim Group Management Report as of June

More information

Stockholders Newsletter

Stockholders Newsletter k Cover Picture Stockholders Newsletter F i n a n c i a l r e p o r t a s o f S e p t e m b e r 3 0, 2 0 1 1 After a good third quarter: Bayer confirms Group outlook Contents Interim Group management Report

More information

Cautionary Statements Regarding Forward-Looking Information

Cautionary Statements Regarding Forward-Looking Information Investor Handout December 2016 Cautionary Statements Regarding Forward-Looking Information Certain statements contained in this communication may constitute forward-looking statements. Actual results could

More information

Stockholders Newsletter Financial Report as of September 30, 2013

Stockholders Newsletter Financial Report as of September 30, 2013 Stockholders Newsletter Financial Report as of September 30, k Cover Picture Third quarter of : Bayer continues positive business momentum Contents Interim Group management Report as of September 30,...4

More information

ZEBRA TECHNOLOGIES SECOND-QUARTER 2016 RESULTS. August 9, 2016

ZEBRA TECHNOLOGIES SECOND-QUARTER 2016 RESULTS. August 9, 2016 ZEBRA TECHNOLOGIES SECOND-QUARTER 2016 RESULTS August 9, 2016 Anders Gustafsson Chief Executive Officer Mike Smiley Chief Financial Officer 2 Safe Harbor Statement Statements made in this presentation

More information

Interim Report. First Quarter of Strong start to the year for Bayer

Interim Report. First Quarter of Strong start to the year for Bayer Interim Report First Quarter of Strong start to the year for Bayer 2 Bayer Interim Report Key Data Bayer Group Key Data Change Full Year million million % million Sales 10,555 12,117 + 14.8 42,239 Change

More information

Stockholders Newsletter

Stockholders Newsletter Stockholders Newsletter Financial Report as of September 30, Bayer continues on path of growth in third quarter 8 For direct access to a chapter, simply click on its name. R Bayer Group Key Data 2 Interim

More information

January March 2010 Conference Call. Georg Denoke Member of the Executive Board & CFO 4 May 2010

January March 2010 Conference Call. Georg Denoke Member of the Executive Board & CFO 4 May 2010 January March 2010 Conference Call Georg Denoke Member of the Executive Board & CFO 4 May 2010 Disclaimer This presentation contains forward-looking statements about Linde AG ( Linde ) and their respective

More information

Charts on Q1 2017/18 Facts & Figures

Charts on Q1 2017/18 Facts & Figures Charts on Q1 Facts & Figures Ticker: TKA (Share) TKAMY (ADR) February 2018 Strong earnings in Q1 confirming FY expectations SWF Portfolio reshaping towards a Diversified Industrial Due Diligence and Signing

More information

News Release. Bayer shows strong performance Acquisition of Monsanto agreed. Third quarter of 2016:

News Release. Bayer shows strong performance Acquisition of Monsanto agreed. Third quarter of 2016: News Release Bayer AG Corporate Brand, Communications & Government Relations 51368 Leverkusen Germany Phone +49 214 30-0 www.news.bayer.com Third quarter of 2016: Bayer shows strong performance Acquisition

More information

Appvion, Inc. Earnings Review Second Quarter August 10, 2016

Appvion, Inc. Earnings Review Second Quarter August 10, 2016 Appvion, Inc. Earnings Review Second Quarter 2016 August 10, 2016 Forward-Looking Statements This presentation contains forward-looking statements. The words will, may, should, believes, anticipates, intends,

More information

Investor Conference. London, August 6, First Half 2003 Results

Investor Conference. London, August 6, First Half 2003 Results Investor Conference London, August 6, 23 First Half 23 Results Safe Harbor This presentation contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management.

More information

LANXESS Q Financial Summary for Investors and Analysts

LANXESS Q Financial Summary for Investors and Analysts LANXESS Q2 2007 Financial Summary for Investors and Analysts EBITDA pre exceptionals rises by 5.0% EBITDA margin pre exceptionals at 12.2% compared to 11.5% EBIT pre exceptionals increases by 9.4% Sales

More information

February 21, Fourth Quarter 2018 Results

February 21, Fourth Quarter 2018 Results February 21, 2019 Fourth Quarter 2018 Results Forward-looking statements This presentation, as well as other statements made by Delphi Technologies PLC (the Company ), contains forward-looking statements

More information

Credit Suisse Healthcare Conference

Credit Suisse Healthcare Conference Credit Suisse Healthcare Conference Murdo Gordon Head, Worldwide Markets November 10, 2015 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects

More information

Full Year 2018 Results. 27 February 2019

Full Year 2018 Results. 27 February 2019 Full Year 2018 Results 27 February 2019 1. Key Highlights and Financial Summary Strong financial performance across all segments and progress made on all aspects of the strategic framework Financial Highlights

More information

Molecular Diagnostic Solutions for Urologic Cancer

Molecular Diagnostic Solutions for Urologic Cancer 2018 All rights reserved 1 Molecular Diagnostic Solutions for Urologic Cancer 2017 Full Year Financial Results February 22, 2018 2 Forward Looking Statement This presentation contains forward-looking statements

More information

Full Year results and outlook

Full Year results and outlook PRESENTATION TO INVESTORS & ANALYSTS Full Year results and outlook David Banfield, Group CEO 29 August 2018 for 12 months 1 July 2017 30 June 2018 Strong international performance drives double digit earnings

More information

H Results. H Results

H Results. H Results 1 H1 17 Highlights Market demand continue to increase (+2.0) Net Sales strong increase 12.6, driven by strong Cooking Own brand business performance +21 EBITDA adjusted* increase by 13.0, positively impacted

More information

Third Quarter 2018 Teleconference Supplemental Data

Third Quarter 2018 Teleconference Supplemental Data Third Quarter 2018 Teleconference Supplemental Data Cautionary Statement Forward-Looking Information This communication contains forward looking statements as that term is defined in the Private Securities

More information

Aegis Group plc Half Year Results. 27 August 2010

Aegis Group plc Half Year Results. 27 August 2010 Aegis Group plc 2010 Half Year Results 27 August 2010 Agenda Introduction John Napier, Chairman Aegis Group overview Jerry Buhlmann, CEO Divisional review Aegis Media - Jerry Buhlmann, CEO Synovate Robert

More information

Investor Handout Q Results

Investor Handout Q Results Investor Handout Q3 2002 Results Table Of Contents Safe Harbour 1 Performance 2 A Far-Reaching Transformation 12 Strategic Priorities 19 Financials 29 2 Safe Harbor This presentation contains forward-looking

More information

KION GROUP AG Q Update Call. Gordon Riske (CEO), Anke Groth (CFO) Frankfurt, 26 July 2018

KION GROUP AG Q Update Call. Gordon Riske (CEO), Anke Groth (CFO) Frankfurt, 26 July 2018 KION GROUP AG Q2 Update Call Gordon Riske (CEO), Anke Groth (CFO) Frankfurt, 26 July Agenda 1. Highlights 2. Market Update 3. Financial Update 4. Outlook 2 KION GROUP AG Q2 Update Call 26 July Q2 Strategic

More information

Quarter and year ended 31 December Financial results & business update

Quarter and year ended 31 December Financial results & business update Quarter and year ended 31 December 2012 Financial results & business update 26 February 2013 Disclaimer Any remarks that we may make about future expectations, plans and prospects for the company constitute

More information

Announcement of Q Results

Announcement of Q Results Announcement of Q3 2008 Results Conference Call October 15, 2008 2:00 p.m. CEST Dr. Axel Herberg, CEO Hans-Jürgen Wiecha, CFO 0 Disclaimer This presentation may contain certain forward-looking statements,

More information

UDG Healthcare plc Interim Results Presentation FY17. London Stock Exchange, 23 rd May 2017

UDG Healthcare plc Interim Results Presentation FY17. London Stock Exchange, 23 rd May 2017 UDG Healthcare plc Interim Results Presentation FY17 London Stock Exchange, 23 rd May 2017 Forward looking statements This Presentation has been prepared by UDG Healthcare plc and contains certain forward-looking

More information

Stockholders Newsletter

Stockholders Newsletter k Cover Picture Stockholders Newsletter F i n a n c i a l r e p o r t a s o f s e p t e m b e r 3 0, 2 0 1 0 Third quarter of : Bayer lifts sales and earnings again Contents Interim Group management Report

More information

Carl Zeiss Meditec Group Analyst Conference 2016/17

Carl Zeiss Meditec Group Analyst Conference 2016/17 Analyst Conference 2016/17 Dr Ludwin Monz, CEO Dr Christian Müller, CFO December 8, 2017 1 Disclaimer This presentation does not constitute or form part of, and should not be construed as, an offer or

More information

4 TH QUARTER AND FULL YEAR 2012 RESULTS

4 TH QUARTER AND FULL YEAR 2012 RESULTS 4 TH QUARTER AND FULL YEAR 2012 RESULTS CONFERENCE CALL & WEBCAST FEBRUARY 11, 2013 5:00 PM ET NYSE: NLSN SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS The following discussion contains forward-looking statements,

More information

May 9, First Quarter 2018 Results

May 9, First Quarter 2018 Results May 9, 2018 First Quarter 2018 Results Forward-looking statements This presentation, as well as other statements made by Delphi Technologies PLC (the Company ), contain forward-looking statements that

More information

Investor Handout Q2 2013

Investor Handout Q2 2013 Investor Handout Q2 2013 August 2013 This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown

More information

Spring Investor Conference Werner Wenning CFO and Member of the Board

Spring Investor Conference Werner Wenning CFO and Member of the Board Spring Investor Conference 2002 Werner Wenning CFO and Member of the Board Safe Harbour This presentation contains forward-looking statements based on current assumptions and forecasts made by Bayer Group

More information

Another record year for Bayer good progress with the acquisition of Monsanto

Another record year for Bayer good progress with the acquisition of Monsanto News Release Bayer AG Communications and Public Affairs 51368 Leverkusen Germany Phone +49 214 30-0 www.news.bayer.com Fiscal 2016: Another record year for Bayer good progress with the acquisition of Monsanto

More information

REUTERS/Michaela Rehle THOMSON REUTERS FOURTH-QUARTER & FULL-YEAR 2010 RESULTS FEBRUARY 10, 2011

REUTERS/Michaela Rehle THOMSON REUTERS FOURTH-QUARTER & FULL-YEAR 2010 RESULTS FEBRUARY 10, 2011 REUTERS/Michaela Rehle THOMSON REUTERS FOURTH-QUARTER & FULL-YEAR 2010 RESULTS FEBRUARY 10, 2011 Agenda Welcome / Introduction Frank Golden Full-Year Results & Highlights Tom Glocer Full-Year 2010 Results

More information

January March Conference Call. Georg Denoke Member of the Executive Board and CFO 04 May 2012

January March Conference Call. Georg Denoke Member of the Executive Board and CFO 04 May 2012 January March 2012 Conference Call Georg Denoke Member of the Executive Board and CFO 04 May 2012 Disclaimer This presentation contains forward-looking statements about Linde AG ( Linde ) and their respective

More information

HELLA Investor Update FY 2017/18

HELLA Investor Update FY 2017/18 HELLA Investor Update FY 2017/18 Conference Call on August 10, 2018 Dr. Rolf Breidenbach, CEO Bernard Schäferbarthold, CFO HF-7761DE_C (2012-12) Disclaimer This document was prepared with reasonable care.

More information

Cautionary Statements Regarding Forward-Looking Information

Cautionary Statements Regarding Forward-Looking Information Investor Handout November 2016 Cautionary Statements Regarding Forward-Looking Information Certain statements contained in this communication may constitute forward-looking statements. Actual results could

More information

Conference Call Q Results. Analysts Conference Call 30 April 2015

Conference Call Q Results. Analysts Conference Call 30 April 2015 Conference Call Q1 2015 Results Analysts Conference Call 30 April 2015 Disclaimer This presentation contains forward-looking statements about Linde AG ( Linde ) and their respective subsidiaries and businesses.

More information

2017 Annual General Meeting 2 May 2017

2017 Annual General Meeting 2 May 2017 2017 Annual General Meeting 2 May 2017 Forward Looking Statements This presentation contains forward-looking statements that reflect GrandVision s current views with respect to future events and financial

More information

First Quarter 2016 Business Update

First Quarter 2016 Business Update Focused. First Quarter 2016 Business Update Innovative. Investor Presentation April 27, 2016 Performance Driven. Disclaimer Statement Regarding Safe Harbor For Forward-Looking Statements This presentation

More information

Q Earnings Presentation August 2, 2018

Q Earnings Presentation August 2, 2018 Q2 2018 Earnings Presentation August 2, 2018 Safe Harbor Statement Safe Harbor Statement under the Private Securities Act of 1995: Statements in this news release that are forward-looking statements are

More information

Q Earnings Call February 20, 2019

Q Earnings Call February 20, 2019 Q4 2018 Earnings Call February 20, 2019 1 Forward-looking statements Safe Harbor Statement This release contains forward-looking statements, which may concern our plans, objectives, outlook, goals, strategies,

More information

Merck FY/Q Financial Summary for Investors and Analysts

Merck FY/Q Financial Summary for Investors and Analysts Merck FY/Q4 2014 Financial Summary for Investors and Analysts Strategic progress and delivery of results in 2014: Closing and successful integration of AZ Electronic Materials Announcement of Sigma-Aldrich

More information

HELLA Investor Update H1 FY 2017/18

HELLA Investor Update H1 FY 2017/18 HELLA Investor Update 2017/18 Conference Call on January 11, 2018 Dr. Rolf Breidenbach, CEO Bernard Schäferbarthold, CFO HF-7761DE_C (2012-12) Disclaimer This document was prepared with reasonable care.

More information

Q Earnings Call. April 24, 2013

Q Earnings Call. April 24, 2013 Q2 2013 Earnings Call April 24, 2013 Forward-Looking Statements and Non-GAAP Measures Forward-Looking Statements -- This presentation contains certain forward-looking statements within the meaning of the

More information